Ardsley Advisory Partners decreased its position in Amicus Therapeutics, Inc. (NASDAQ:FOLD) by 9.6% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 330,000 shares of the biopharmaceutical company’s stock after selling 35,000 shares during the period. Ardsley Advisory Partners owned about 0.20% of Amicus Therapeutics worth $4,749,000 as of its most recent SEC filing.
A number of other institutional investors have also recently bought and sold shares of the business. Two Sigma Investments LP raised its holdings in Amicus Therapeutics by 29.6% in the 4th quarter. Two Sigma Investments LP now owns 336,940 shares of the biopharmaceutical company’s stock valued at $4,849,000 after acquiring an additional 77,049 shares in the last quarter. QS Investors LLC raised its holdings in Amicus Therapeutics by 4.9% in the 4th quarter. QS Investors LLC now owns 159,008 shares of the biopharmaceutical company’s stock valued at $2,288,000 after acquiring an additional 7,483 shares in the last quarter. Jafra Capital Management LP acquired a new position in Amicus Therapeutics in the 4th quarter valued at approximately $969,000. Franklin Resources Inc. raised its holdings in Amicus Therapeutics by 12.3% in the 4th quarter. Franklin Resources Inc. now owns 3,718,899 shares of the biopharmaceutical company’s stock valued at $53,515,000 after acquiring an additional 406,499 shares in the last quarter. Finally, Tekla Capital Management LLC raised its holdings in Amicus Therapeutics by 119.6% in the 4th quarter. Tekla Capital Management LLC now owns 604,920 shares of the biopharmaceutical company’s stock valued at $8,705,000 after acquiring an additional 329,426 shares in the last quarter.
In related news, CFO William D. Baird III sold 10,000 shares of the firm’s stock in a transaction on Tuesday, January 2nd. The stock was sold at an average price of $14.72, for a total transaction of $147,200.00. Following the completion of the sale, the chief financial officer now directly owns 105,121 shares of the company’s stock, valued at approximately $1,547,381.12. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, SVP Daphne Quimi sold 8,000 shares of the firm’s stock in a transaction on Tuesday, January 2nd. The shares were sold at an average price of $14.72, for a total value of $117,760.00. Following the sale, the senior vice president now directly owns 62,676 shares of the company’s stock, valued at $922,590.72. The disclosure for this sale can be found here. Insiders have sold a total of 194,120 shares of company stock valued at $2,859,612 over the last ninety days. Insiders own 3.40% of the company’s stock.
A number of brokerages have recently issued reports on FOLD. Zacks Investment Research raised Amicus Therapeutics from a “sell” rating to a “hold” rating in a report on Tuesday, March 6th. ValuEngine raised Amicus Therapeutics from a “sell” rating to a “hold” rating in a report on Friday, February 2nd. BidaskClub raised Amicus Therapeutics from a “sell” rating to a “hold” rating in a report on Thursday, December 21st. Robert W. Baird set a $20.00 target price on Amicus Therapeutics and gave the stock a “buy” rating in a report on Wednesday, February 7th. Finally, Cowen reissued a “buy” rating and issued a $22.00 target price on shares of Amicus Therapeutics in a report on Wednesday, January 10th. Four analysts have rated the stock with a hold rating and six have given a buy rating to the stock. The company presently has an average rating of “Buy” and an average target price of $19.06.
Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) opened at $14.91 on Monday. Amicus Therapeutics, Inc. has a twelve month low of $6.41 and a twelve month high of $17.40. The firm has a market capitalization of $2,480.00, a price-to-earnings ratio of -17.75 and a beta of 1.59. The company has a current ratio of 5.60, a quick ratio of 5.53 and a debt-to-equity ratio of 0.47.
Amicus Therapeutics (NASDAQ:FOLD) last released its quarterly earnings results on Wednesday, February 28th. The biopharmaceutical company reported ($0.41) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.30) by ($0.11). Amicus Therapeutics had a negative net margin of 769.03% and a negative return on equity of 71.06%. The business had revenue of $14.73 million for the quarter, compared to analyst estimates of $14.50 million. equities analysts anticipate that Amicus Therapeutics, Inc. will post -1.26 earnings per share for the current fiscal year.
TRADEMARK VIOLATION NOTICE: “Ardsley Advisory Partners Sells 35,000 Shares of Amicus Therapeutics, Inc. (FOLD)” was first reported by The Ledger Gazette and is the property of of The Ledger Gazette. If you are accessing this piece on another site, it was stolen and republished in violation of U.S. & international trademark and copyright law. The legal version of this piece can be viewed at https://ledgergazette.com/2018/03/12/ardsley-advisory-partners-sells-35000-shares-of-amicus-therapeutics-inc-fold.html.
About Amicus Therapeutics
Amicus Therapeutics, Inc is a biotechnology company. The Company is engaged in the discovery, development and commercialization of a set of treatments for patients living with devastating rare and orphan diseases. Its lead product, migalastat HCl is a small molecule that can be used as a monotherapy and in combination with enzyme replacement therapy (ERT) for Fabry disease.
Receive News & Ratings for Amicus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amicus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.